Clinical trials: Thalidomide, completed
Lung Cancer
Combination Chemotherapy Plus Thalidomide in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Combining thalidomide with chemotherapy may kill more tumor cells and be an effective treatment for stage IIIB or stage IV non-small cell…
- Trial name
- NCT00025285
- Testing
- carboplatin, irinotecan hydrochloride, thalidomide
- Where
- 5 sites in United States
- Volunteers
- 46 people
- Sponsor
- Wake Forest University Health Sciences
Acquired Immunodeficiency Syndrome, Burning Mouth Syndrome
Thalidomide to Treat Oral Lesions in HIV-Infected Patients
This study will test the effectiveness of topical thalidomide in healing mouth sores in HIV infected patients. Oral (PO) thalidomide heals these sores at a dose of 200 mg per day.
- Conditions
- Acquired Immunodeficiency Syndrome, Burning Mouth Syndrome, HIV Infection
- Trial name
- NCT00001524
- Testing
- Thalidomide
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
Multiple Myeloma de Novo Treatment
Multiple Myeloma Treated With Thalidomide Before Autotransplant or With Conventional Chemotherapy and as Consolidation/Maintenance Treatment in Young and Elderly Patients : 3 Randomized Studies.
The aim of the study was to evaluate efficacy and tolerability of Thalidomide in first-line treatment of multiple myeloma as induction treatment in young patients, with Dexamethasone before autotransplant, and in elderly patients…
- Trial name
- MAG 2002 (NCT01070862)
- Testing
- Thalidomide, Dexamethasone, Vincristin , Adriamycin, Dexamethasone = VAD, Thalidomide, melphalan, endoxan, dexamethasone (MCDex-Thal)
- Where
- 3 sites in France
- Sponsor
- University Hospital, Caen
Obscure Gastrointestinal Bleeding, Angiodysplasia
Long-term Effects of Thalidomide for Recurrent Gastrointestinal Bleeding Due to Vascular Malformation
Background: Repeated episodes of bleeding from gastrointestinal vascular malformations refractory to endoscopic or surgical therapy often pose a major therapeutic challenge.
- Conditions
- Obscure Gastrointestinal Bleeding, Angiodysplasia, Gastric Antral Vascular Ectasia, Thalidomide
- Trial name
- NCT00964496
- Testing
- Thalidomide, Iron
- Volunteers
- 55 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Multiple Myeloma
Preventive Treatment of VETD in Patients With Multiple Myeloma Receiving Chemotherapy With Thalidomide or Lenalinomide.
Patients with multiple myeloma have seen their survival rate strongly improved with the use of new anti angiogenic agents. Among them, the new chemotherapy with thalidomide or lenalinomide are frequently successfully suggested in…
- Trial name
- NCT01268774
- Volunteers
- 529 people
- Sponsor
- LEO Pharma
Leukemia
Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy, such as fludarabine, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00096018
- Testing
- fludarabine phosphate, thalidomide
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Roswell Park Cancer Institute
Liver Cancer
Thalidomide Plus Interferon Alfa in Treating Patients With Progressive Liver Cancer That Cannot be Surgically Removed
Phase II trial to study the effectiveness of thalidomide plus interferon alfa in treating patients who have progressive liver cancer that cannot be surgically removed.
- Trial name
- NCT00006006
- Testing
- recombinant interferon alfa, thalidomide
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC)
The primary objective of this study is to evaluate PSA response rates of the combination of Doxil and Thalidomide in patients with AIPC who have failed chemotherapy.
- Trial name
- NCT00307294
- Testing
- Thalidomide, Doxil
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Pittsburgh
Prostate Cancer
Preoperative Thalidomide Followed By Radical Retropubic Prostatectomy In Select Patients With Locally Advanced Prostate Cancer
The goal of this clinical research study is to find out whether it is safe to treat patients diagnosed with locally advanced prostate cancer with the drug Thalidomide before removing the tumor (radical retropubic prostatectomy).
- Trial name
- NCT00038181
- Testing
- Thalidomide
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Thalidomide may stop the growth of cancer cells by blocking blood flow to the cancer.
- Trial name
- NCT00287872
- Testing
- bortezomib, thalidomide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Kidney Cancer
Interferon Alfa-2b With or Without Thalidomide in Treating Patients With Metastatic or Unresectable Kidney Cancer
RATIONALE: Interferon alfa-2b may interfere with the growth of the cancer cells. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor.
- Trial name
- NCT00005966
- Testing
- recombinant interferon alfa, thalidomide
- Where
- 14 sites in United States, Australia and 2 more
- Sponsor
- Eastern Cooperative Oncology Group
Thalassemia, Beta
Clinical Experience of Thalidomide in Thalassemic Patients
Objectives Primary objective: To determine the efficacy and safety of the combination therapy of Hydroxyurea and thalidomide in beta-thalassemia patients.
- Trial name
- NCT05132270
- Testing
- hydroxyurea and thalidomide
- Where
- Pakistan
- Volunteers
- 135 people
- Sponsor
- Children's Hospital Karachi
Endometrial Adenoacanthoma, Endometrial Adenocarcinoma
Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer
Phase II trial to study the effectiveness of thalidomide in treating patients who have recurrent or persistent endometrial cancer. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor
- Conditions
- Endometrial Adenoacanthoma, Endometrial Adenocarcinoma, Endometrial Adenosquamous Cell Carcinoma, Endometrial Clear Cell Carcinoma
- Trial name
- NCT00025467
- Testing
- thalidomide, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Idiopathic Pulmonary Fibrosis, Cough
Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide
Idiopathic Pulmonary Fibrosis (IPF) is a rapidly progressive lung disorder that is often associated with a chronic, intractable cough.
- Trial name
- NCT00600028
- Testing
- Thalidomide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Johns Hopkins University
Intraocular Melanoma, Melanoma (Skin)
Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma
RATIONALE: Drugs used in chemotherapy, such as temozolomide and lomustine, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00072345
- Testing
- lomustine, temozolomide, thalidomide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Intraocular Melanoma, Melanoma (Skin)
Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of melanoma by stopping blood flow to the tumor.
- Trial name
- NCT00005815
- Testing
- temozolomide, thalidomide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
Melphalan, Prednisone, Thalidomide and Defibrotide in Relapsed Multiple Myeloma Patients
This study will evaluate the safety and the efficacy of the association of Melphalan/ Prednisone/Thalidomide/Defibrotide (MPTD) as salvage treatment in advanced and refractory myeloma patients.
- Trial name
- MPTD (NCT00406978)
- Testing
- Prednisone, Melphalan, Thalidomide
- Where
- 5 sites in Italy
- Volunteers
- 24 people
- Sponsor
- Silvio Aime
Multiple Myeloma and Plasma Cell Neoplasm
Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma
RATIONALE: Thalidomide may stop the growth of multiple myeloma by stopping blood flow to the tumor. It is not yet known whether combining thalidomide with prednisone and giving them after autologous stem cell transplantation may…
- Trial name
- NCT00049673
- Testing
- prednisone, thalidomide
- Where
- 18 sites in Canada
- Volunteers
- 332 people
- Sponsor
- NCIC Clinical Trials Group
Multiple Myeloma
Tandem Transplantation in Multiple Myeloma (MM) Patients With <12 Months of Prior Treatment
The two objectives of this study are: To increase the 2-year event-free survival from 55%, established with Total Therapy II (UARK 98-026), to 75% in myeloma patients with cytogenetic abnormalities, and from 80%, established with…
- Trial name
- NCT00670631
- Testing
- tandem autologous transplantation
- Volunteers
- 46 people
- Sponsor
- Guido Tricot
Sjogren's Syndrome, Xerostomia
Pilot Study of Thalidomide to Treat Sjogren's Syndrome
This study will evaluate the safety and effectiveness of thalidomide in treating Sjogren's syndrome. In this autoimmune disease, the immune system attacks the body's tear glands and salivary glands, causing dry mouth and dry…
- Trial name
- NCT00001599
- Testing
- Thalidomide
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)